ARK Genomic Revolution ETF (09KE)
XHAM 
Summary
09KE Chart
Best ETF Areas of June
Biotech, China, insurance and healthcare ETFs led June gains as strong earnings, AI optimism and easing geopolitical fears lifted markets.
June's Top ETFs: Biotech & China Semiconductors Surge
June has been a month full of excitement in the ETF market. While commercial space and AI infrastructure attracted a significant amount of investor attention, biotechnology exposure comprises four out of the five top-performing equity ETFs as of June 29.
Biotech ETFs Put Up Strong Show in 1H 2026: More Gains Ahead?
Biotech ETFs are surging in 2026 as a friendlier FDA, strong M&A activity and AI-driven drug discovery fuel optimism for more upside.
ARK Genomic Revolution ETF (09KE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has ARK Genomic Revolution ETF ever had a stock split?
ARK Genomic Revolution ETF Profile
| XHAM Exchange | US Country |
Overview
The fund is a cutting-edge investment vehicle focusing on the burgeoning field of genomics, operating as an actively-managed exchange-traded fund (ETF). It seeks to capitalize on the transformative potential of genomics across various sectors, including healthcare, information technology, materials, energy, and consumer discretionary. By investing primarily in both domestic and foreign equity securities of companies at the forefront of the genomics revolution, the fund aims to offer investors unique exposure to this dynamic and rapidly evolving industry. Despite its concentrated theme, the fund maintains a broad perspective by integrating firms from multiple sectors that are instrumental in advancing genomics-related technologies and applications. It is non-diversified, indicating a focused investment strategy in companies specifically selected for their relevance to the genomics revolution.
Products and Services
- Equity Securities of Genomics Revolution Companies
This product is the centerpiece of the fund's investment strategy, comprising a significant portion of its assets in domestic and foreign equity securities of companies leading the genomics revolution. By focusing on sectors such as healthcare, information technology, materials, energy, and consumer discretionary, the fund targets entities that are integral to the advancement of genomics. This includes firms engaged in genetic sequencing, gene editing, biotechnological innovation, and other areas that contribute to the evolution of genomics.
